Novel 6β-acylaminomorphinans with analgesic activity.

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Neuroscience

Background:

• Aminomorphinans represent a novel class of opioid analgesics with promising in vitro and in vivo profiles.
• Traditional opioids like morphine, while effective, carry significant risks, notably respiratory depression.

Purpose of the Study:

• To synthesize and pharmacologically evaluate novel 6β-acylaminomorphinans.
• To assess the analgesic efficacy and receptor binding profiles of these new compounds.
• To determine if these novel compounds mitigate opioid-induced respiratory depression.

Main Methods:

• Stereoselective synthesis of 6β-morphinamine and 6β-codeinamine via Mitsunobu reaction.
• Acylation of aminomorphinans with substituted cinnamic acids to create cinnamoyl derivatives.
• In vitro opiate receptor binding assays and in vivo rodent analgesia studies.

Main Results:

• Cinnamoyl morphinamines exhibited moderate affinity for opiate receptors, with selectivity for mu-opioid receptors.
• Cinnamoyl codeinamines demonstrated specific affinity for mu-opioid receptors.
• The lead compound, 6β-cinnamoylmorphinamine, displayed significant analgesic activity mediated by mu and delta receptors, equipotent to morphine.
• Crucially, the lead compound was devoid of respiratory depression in vivo.

Conclusions:

• Novel 6β-acylaminomorphinans possess potent analgesic properties.
• The lead compound demonstrates a potentially improved safety profile compared to morphine due to the absence of respiratory depression.
• These findings highlight the therapeutic potential of this new class of opioid analgesics.